Open Access

An analysis of the expression and function of myeloid differentiation factor 88 in human osteosarcoma

  • Authors:
    • Jun Chen
    • Jian He
    • Yue Yang
    • Jiannong Jiang
  • View Affiliations

  • Published online on: August 13, 2018     https://doi.org/10.3892/ol.2018.9297
  • Pages: 4929-4936
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the expression and function of myeloid differentiation factor 88 (MyD88) in osteosarcoma. Immunohistochemical staining was used to detect MyD88 protein in osteosarcoma tissues and matched normal bone tissues. The association between MyD88 expression and the clinical characteristics of patients with osteosarcoma was analyzed. Furthermore, survival analysis of patients with osteosarcoma was performed to study the association between MyD88 expression and patient prognosis. Finally, the effect of the MyD88 inhibitor, ST2825, on the proliferation and apoptosis of the human osteosarcoma cell line U2OS was examined. Additionally, cell proliferation, invasion and apoptosis were examined using an MTT assay, Transwell assay and Annexin V‑fluorescein isothiocyanate staining kit, respectively. The expression of proteins associated with the NF‑κB signaling pathway was analyzed by western blotting. The positive expression rate of MyD88 in osteosarcoma and normal bone tissues was 71.4 and 6.1%, respectively. Statistical analysis demonstrated that MyD88 was not associated with gender, age, histological type or tumor location, but that it was associated with Enneking stage and tumor metastasis (P<0.05). According to the survival analysis, patients with osteosarcoma in the high MyD88 expression group displayed a reduced overall survival rate (P<0.05). Furthermore, inhibition of MyD88 by ST2825 in U2OS cells resulted in a marked decrease in cellular proliferation and migration, and an increase in the rate of apoptosis (P<0.05). Notably, ST2825 significantly decreased cyclin D1, matrix metallopeptidase‑9 and nucleus p65 expression, but increased cleaved‑caspase 3 expression in ST2825‑treated U2OS cells (P<0.05). The results of the present study indicated that MyD88 expression is associated with the progression of osteosarcoma and may be a potential therapeutic target for the treatment of osteosarcoma.
View Figures
View References

Related Articles

Journal Cover

October-2018
Volume 16 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen J, He J, Yang Y and Jiang J: An analysis of the expression and function of myeloid differentiation factor 88 in human osteosarcoma. Oncol Lett 16: 4929-4936, 2018
APA
Chen, J., He, J., Yang, Y., & Jiang, J. (2018). An analysis of the expression and function of myeloid differentiation factor 88 in human osteosarcoma. Oncology Letters, 16, 4929-4936. https://doi.org/10.3892/ol.2018.9297
MLA
Chen, J., He, J., Yang, Y., Jiang, J."An analysis of the expression and function of myeloid differentiation factor 88 in human osteosarcoma". Oncology Letters 16.4 (2018): 4929-4936.
Chicago
Chen, J., He, J., Yang, Y., Jiang, J."An analysis of the expression and function of myeloid differentiation factor 88 in human osteosarcoma". Oncology Letters 16, no. 4 (2018): 4929-4936. https://doi.org/10.3892/ol.2018.9297